Kura Oncology, Inc. (NasdaqGS: KURA)
Health Care · Biotechnology · US
$10.60
+0.76% today · +3.4% 1Y
Kura Oncology, Inc. (NasdaqGS: KURA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $942.98M and employs 260 people.
Over the last twelve months the share price has gained 3.4%, trading between 7.36 and 13.90.
Tweenvest scores Kura Oncology, Inc. across four factors: quality 52/100, value 37/100. Its strongest factor is quality.
KURA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $942.98M
- Revenue (TTM)
- $77.22M
- P/E
- —
- EPS
- -3.36
- Dividend yield
- —
- Beta (5Y)
- 0.47
- 52-week high
- $13.90
- 52-week low
- $7.36
- Avg volume (3M)
- —
- Shares outstanding
- 88.96M
- Employees
- 260
- Next earnings
- —
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- ISIN
- US50127T1097
- Listed since
- Sep 16, 2015
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Philogen S.p.A.BIT: PHIL | $991.45M | €22.00 | +0.69% |
| Jiangsu Aidea Pharmaceutical Group Co., Ltd.SHSE: 688488 | $989.43M | CN¥15.75 | -5.29% |
| Basilea Pharmaceutica AGSWX: BSLN | $979.21M | CHF65.50 | -1.95% |
| Shanghai Haohai Biological Technology Co., Ltd.SEHK: 6826 | $943.26M | HK$16.11 | +0.25% |
| Ascletis Pharma Inc.SEHK: 1672 | $936.85M | HK$6.96 | -14.23% |
| Ingenia Therapeutics Inc.KOSDAQ: A950260 | $932.34M | ₩25,350.00 | -12.13% |
| LongBio Pharma (Suzhou) Co., Ltd.SEHK: 1779 | $926.52M | HK$98.00 | -3.64% |
| MoonLake ImmunotherapeuticsNasdaqCM: MLTX | $920.85M | $10.82 | +2.27% |
Figures last refreshed Oct 11, 2026.